5 and 1.4 pregnancies per 100 person-years, respectively Palbociclib manufacturer [43]. To project a possible range for the risk of teratogenic events, we used one-way and two-way sensitivity analyses to vary all uncertain parameters. The plausible range for

each parameter was based on 95% CIs when available, published data, or expert opinion. In the base case simulation model analysis, mean projected life expectancy for women receiving an efavirenz-based first-line ART regimen starting at CD4<350 cells/μL regardless of childbearing potential was 28.91 life years (Table 3). In comparison, mean life expectancy for women who delayed efavirenz use and were treated with an alternative initial ART regimen which did not contain efavirenz was 28.02 years. The life expectancy gain attributable to using an efavirenz-based initial antiretroviral regimen was 0.89 years. For

women receiving an efavirenz-based initial regimen, mean total exposure time to efavirenz was 4.07 years per woman. For women delaying efavirenz use and receiving alternate first-line therapy, mean exposure time to efavirenz was 3.37 years per woman. In the sensitivity analysis, we examined Fludarabine how the life expectancy gains attributed to initial and delayed use of efavirenz varied with changes in selected simulation model input parameters in one-way sensitivity analyses (Table 3). Results were most sensitive to changes in HIV RNA suppression and CD4 cell count gains attributable to ART, mortality attributable to AIDS, and the discount rate. The incremental life expectancy gain with efavirenz-based first-line ART ranged from 0.44 to 0.78 years of life as viral suppression rates of the first-line regimens were increased by 20% to a maximum of 95% and decreased by 20% (Table 3). When CD4 gains for first-line ART were increased

and decreased by 50%, incremental gains in life expectancy attributable to first-line efavirenz ranged from 0.89 to 0.67 years. For women delaying efavirenz use, estimated life expectancy increased from 28.02 to 28.74 years when the CD4 gains for the first and third regimens in the sequence were increased from 190 cells/μL at 48 weeks to 203cells/μL at 48 weeks for the first regimen and from 86 cells/μL at 16 weeks to Montelukast Sodium 273 cells/μL at 96 weeks for the second regimen, as reported in the literature. This increase in survival for women delaying efavirenz narrowed incremental survival gains attributable to first-line efavirenz use to 0.17 years (base case: 0.89 years). When an initial nevirapine-based regimen was substituted for the recommended efavirenz-based therapy and ART was initiated at CD4<250 cells/μL, the mean life expectancy for women receiving the nevirapine-based therapy was 25.49 years. For an efavirenz-based first-line ART regimen starting at CD4<250 cells/μL, estimated survival was 27.08 years. Time on initial treatment using a nevirapine-based regimen was 3.02 years compared with 4.00 years with first-line efavirenz.